Technology | 2016.04.12
Biotech aiming to use CRISPR gene editing to treat rare diseases to go public - STAT
| STAT | Biotech aiming to use CRISPR gene editing to treat rare diseases to go public STAT Intellia Therapeutics, a biotech company that aims to use a revolutionary gene editing technology to treat rare diseases, is looking to raise as much as $120 million in an IPO to advance its early-stage science. The company, based in Cambridge, Mass ... Gene- editing firm Intellia announces IPO, deal with Regeneron Gene editing biotech Intellia Therapeutics files for a $120 million IPO Regeneron inks deal to develop drugs using gene editing technology CRISPR/Cas9 |
For more information, please visit
http://news.google.com/news/url?sa=t&fd=[...]/11/crispr-gene-edit-intellia/
Follow us on
Instagram is adding automatic in-app text translation - The Verge views: 1528
Here’s a ‘Brand-New’ Massive Multilingual Dataset for Machine Translation views: 1524